A dysregulated inflammatory response is observed in various diseases, such as rheumatoid arthritis, diabetes, cancer, and Alzheimer's disease as well as pulmonary, cardiovascular, and autoimmune diseases. Inflammation involves a complex network of many mediators, a variety of cells, and execution of multiple pathways.
Traditionally, therapeutic regimens for inflammation include the use of steroidal and non-steroidal anti-inflammatory agents. However, these drugs may provoke severe adverse effects, including osteoporosis, gastrointestinal abnormalities, cardiovascular events, and renal disorders. Moreover, drug resistance may occur in a subpopulation of patients. There is an urgent need to explore new anti-inflammatory agents with selective effects and lower toxicity. Although various in vivo and in vitro models are available for anti-inflammatory drug development, wise selection of appropriate animal models is a key step in the early phase of drug development.
Creative Bioarray offers a large number of validated acute, chronic and immune-mediated pharmacological models and a series of preclinical services, enabling customers to screen potential anti-inflammatory agents as well as identify novel therapeutic targets. Screening of compounds can be performed in existing well-characterized animal models or in newly developed animal models customized for specific test items.
We work closely with scientists from academic institutions, pharmaceutical industries or biotechnology companies. Our expert scientists are able to combine different disease models to provide unparalleled ability to distinguish the mode of action of novel compounds. Combining models, such as IBD, fibrosis or asthma, along with biomarker readouts may quickly and cost-effectively reveal a putative mode of action.